Results of a large-scale international survey, released by the World Lupus Federation on World Lupus Day May 10, show a low level of lupus awareness by the general public, revealing a need for increased education and understanding about the disease. Lupus is considered to be a global health problem, with more than…
Lupus remains a poorly known or understood disease, with a recent poll by the Lupus Foundation of America finding 51 percent of respondents worldwide did not even know it is a disease — and one that affects an estimated five million people worldwide. Because such lack of awareness can extent…
Systemic lupus erythematosus (SLE) is a major cause of death in young women that goes largely unrecognized due to its exclusion from an annual nationwide ranking, a new U.S. study shows. Based on these findings, researchers believe that public health and research programs dedicated to the disease are warranted, and…
A new mechanism that helps to maintain immune self-tolerance and prevent autoimmune diseases was discovered using human cells and mice, new research shows. The findings identify a novel pathway that regulates tolerance in B-cells, which may provide a new diagnostic marker and therapeutic targets to…
The Lupus Research Alliance and its newly formed affiliate Lupus Therapeutics will collaborate with Bristol-Myers Squibb (BMS) to test a novel investigational candidate BMS-986165 as a potential therapy for lupus. BMS-986165 is the first of its kind to be tested in lupus. The medicine is a potent,…
Teen and young women with systemic lupus erythematosus (SLE) have a higher risk of adverse pregnancy-related outcomes, including hypertensive disorders, maternal death, preterm birth, spontaneous abortion, and induced abortion, according to researchers. Their study, “Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: a…
Iron deficiency, measured through the size variation of red blood cells, is correlated with increased fatigue in systemic lupus erythematosus (SLE) patients, research shows. The association seems to be independent of age, ethnicity, or geographical location. This is the first time a blood biomarker has been linked to fatigue…
Benlysta (belimumab) reduces disease activity, relapses, and the need for corticosteroids in patients with a high degree of systemic lupus erythematosus (SLE) disease activity, according to a new analysis of a Phase 3 clinical trial. The study, “Efficacy and safety of subcutaneous belimumab in anti‐dsDNA‐positive, hypocomplementemic…
Infection with the Epstein-Barr virus (EBV) that causes mononucleosis can increase a person’s risk of developing any of seven major autoimmune diseases, including systemic lupus erythematosus, new and possibly ground-breaking research indicates. The study, “Transcription factors operate across disease loci, with…
Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of a Phase 3 clinical trial, according to top-line results. Although not statistically significant, the investigational treatment did, however, show…